Results 61 to 70 of about 10,064 (258)

Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome

Pharmaceutics
The discovery of new drugs offers valuable alternatives, particularly for treating diseases that are resistant to existing therapies or involving complex, multi-organ conditions such as metabolic syndrome. Although treatment algorithms are generally well
Wiktoria Górecka, Daria Berezovska, Monika Mrozińska, Grażyna Nowicka, Monika E. Czerwińska   +4 more
doaj   +1 more source

Surfaceome Reprogramming of Stemsomes Promotes Lung Cancer Targeting via Potentiated Receptor–Ligand Interactions

Advanced Science, EarlyView.
This study presents a surfaceome‐reprogramming strategy for mutation‐independent lung cancer therapy by repurposing dexamethasone to prime mesenchymal stem cell‐derived nanovesicles. The engineered vesicles leverage multi‐valent interactions mediated by upregulated adhesion proteins, EPHA2, and NOTCH3.
Geunhye Kim, In Ah Kwon, Bo Seop Jeong, Hyo Seon Kim, Joo‐Hwan Park, Sung Jean Park, Sang‐Rae Lee, Youngki Lee, Dongwoo Khang   +8 more
wiley   +1 more source

Correlations of mRNA Levels among Efflux Transporters, Transcriptional Regulators, and Scaffold Proteins in Non-Small-Cell Lung Cancer

Canadian Journal of Infectious Diseases and Medical Microbiology, 2021
Multidrug resistance (MDR) due to enhanced drug efflux activity of tumor cells can severely impact the efficacy of antitumor therapies. We recently showed that increased activity of the efflux transporter P-glycoprotein (P-gp) associated with activation ...
Xieyi Zhang, Wangyang Liu, Kazue Edaki, Yuta Nakazawa, Hiroki Kamioka, Atsushi Fujita, Ryoichi Onozato, Misa Iijima, Shigeru Tsuchida, Takahiro Arai, Yukiyoshi Fujita, Kenta Mizoi, Takuo Ogihara   +12 more
doaj   +1 more source

Advanced Experiment Design Strategies for Drug Development

Advanced Intelligent Discovery, EarlyView.
Wang et al. analyze 592 drug development studies published between 2020 and 2024 that applied design of experiments methodologies. The review surveys both classical and emerging approaches—including Bayesian optimization and active learning—and identifies a critical gap between advanced experimental strategies and their practical adoption in ...
Fanjin Wang, Anthony Harker, Mohan Edirisinghe, Maryam Parhizkar   +3 more
wiley   +1 more source

Liposomal Delivery of L‐2‐Hydroxyglutarate for Targeting Epigenetic Dysregulation in Osteoarthritis

Advanced NanoBiomed Research, EarlyView.
Osteoarthritis involves cartilage degeneration, inflammation, and epigenetic dysregulation. A liposomal formulation of the TET1 inhibitor L‐2‐hydroxyglutarate to overcome rapid joint clearance was developed. The formulation showed good physicochemical properties, reduced inflammatory and catabolic gene expression in chondrocytes, and alleviated ...
Denise Murgia, Akshay Pandey, Raffaele Spanò, Bianca Martins Estevão, Roberto Palomba, Greta Avancini, Tamaghna Gupta, Ana Maria Lopez Estevez, Stuart B. Goodman, Nidhi Bhutani, Paolo Decuzzi   +10 more
wiley   +1 more source

Three-dimensional Biopharmaceutics and Clinical Considerations of Drugs for Safety and Efficacy: A Review Study [PDF]

Pharmaceutical and Biomedical Research
Background: Several drugs today are described with their molecular structures showcasing symmetrical, dissymmetrical, or asymmetrical configurations. Some drugs showing chirality are racemic or pure enantiomeric forms for clinical practice.
Sunday O. Awofisayo, Akwaowoh E. Akpabio, Emmanuel O. Olorunsola, Matthew I. Arhewoh   +3 more
doaj  

Silymarin and Silybin: Rejuvenating Traditional Remedies with Modern Delivery Strategies

Pharmaceutics
Silymarin, a polyphenolic flavonolignan complex extracted from Silybum marianum (milk thistle), has long been recognized for its hepatoprotective, antioxidant, anti-inflammatory, and anticancer properties.
Xiuyan Li, Han Zhu, Yanhong Wang, Xiwu Zhang, Zhixin Yang, Xueying Yan, Qin Yu   +6 more
doaj   +1 more source

Nitrosylated high density lipoprotein is recognized by a scavenger receptor in rat liver.

Journal of Lipid Research, 1989
In order to assess the presence of specific recognition sites for high density lipoprotein (HDL) in vivo, HDL was nitrosylated with tetranitromethane and the decay and liver uptake were compared with that of native HDL.
M F Kleinherenbrink-Stins, D Schouten, J van der Boom, A Brouwer, D L Knook, T J van Berkel   +5 more
doaj   +1 more source

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

Arthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava, Michelle Petri, Patrick G. Gavin, Eszter Csomor, Philip Z. Brohawn, Daniel Muthas, Adam Platt, Catharina Lindholm, Nicola Ferrari   +8 more
wiley   +1 more source

Multi‐Omic Profiling Reveals Immune Cell Priming Signature Linked to Lupus Prognosis

Arthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is a multiorgan disease with widespread immune dysregulation and significant unmet clinical need. Blood‐based gene expression studies have advanced our understanding of SLE pathogenesis but may overlook critical tissue‐specific mechanisms that drive disease heterogeneity and progression.
Michael A. Smith, Dominic Sinibaldi, Saifur Rahman, Chia‐Chien Chiang, Anna M. Hansen, Jill Henault, Carlos P. Roca, Shu Wang, Kamelia Zerrouki, Rebecca Filippi, Christopher Groves, Zerai Manna, Jun Chu, Michael Davis, Sarthak Gupta, Christopher Morehouse, Melissa de los Reyes, Rachel Ettinger, Roland Kolbeck, Mariana J. Kaplan, Miguel A. Sanjuan, Richard M. Siegel, Sarfaraz A. Hasni, Kerry A. Casey   +23 more
wiley   +1 more source